Why the study?
Does aggressive lipid-lowering therapy reduce coronary heart disease morbidity and mortality in patients with or at risk for CHD?
Does aggressive lipid-lowering therapy reduce coronary heart disease morbidity and mortality in patients with or at risk for CHD?
Aggressive lipid-lowering therapy, including combination therapy and newer statins, is necessary to achieve updated NCEP ATP III guideline targets for LDL-C and HDL-C in patients at risk for CHD.
No takes yet. Share an insight, caveat, or question.
Supports aggressive lipid-lowering to meet LDL-C/HDL-C targets; leaves open prospective validation of outcome benefits.
Daniel J. Rader (2003) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: